| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A Framework for Methodological Choice and Evidence Assessment for Studies Using External Comparators from Real-World Data
|
Gray, Christen M.
|
|
|
43 |
7 |
p. 623-633
|
article
|
| 2 |
A New Drug–Drug Interaction Between Hydroxychloroquine and Metformin? A Signal Detection Study
|
Montastruc, Jean-Louis
|
|
|
43 |
7 |
p. 657-660
|
article
|
| 3 |
Does Ibuprofen Worsen COVID-19?
|
Moore, Nicholas
|
|
|
43 |
7 |
p. 611-614
|
article
|
| 4 |
Drug-Induced Liver Injury and COVID-19 Infection: The Rules Remain the Same
|
Olry, Alexandre
|
|
|
43 |
7 |
p. 615-617
|
article
|
| 5 |
Drug Safety Issues Covered by Lay Media: A Cohort Study of Direct Healthcare Provider Communications Sent between 2001 and 2015 in The Netherlands
|
de Vries, Esther
|
|
|
43 |
7 |
p. 677-690
|
article
|
| 6 |
Evidence of Clinically Meaningful Drug–Drug Interaction With Concomitant Use of Colchicine and Clarithromycin
|
Villa Zapata, Lorenzo
|
|
|
43 |
7 |
p. 661-668
|
article
|
| 7 |
Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety
|
Giovannoni, Gavin
|
|
|
43 |
7 |
p. 635-643
|
article
|
| 8 |
Rates and Costs of Dispensing Naloxone to Patients at High Risk for Opioid Overdose in the United States, 2014–2018
|
Barenie, Rachel E.
|
|
|
43 |
7 |
p. 669-675
|
article
|
| 9 |
Remdesivir in Treatment of COVID-19: A Systematic Benefit–Risk Assessment
|
Davies, Miranda
|
|
|
43 |
7 |
p. 645-656
|
article
|
| 10 |
The International Society of Pharmacovigilance (ISoP) Special Interest Group on Herbal and Traditional Medicines: Towards Progress in Pharmacovigilance for Herbal and Traditional Medicines and Other “Natural Health” Products
|
Barnes, Joanne
|
|
|
43 |
7 |
p. 619-622
|
article
|
Journal description